Table 1.

Clinical, Anthropometric, and Laboratory Data at the Time of Entry Into the Post-treatment Follow-up Period

Characteristic	PIO	PLAC
n	152	138
NGT/IGT	81/71	49/89
Age, y	54.2 ± 0.7	52 ± 0.7
Weight, kg	97.1 ± 1.6	95.3 ± 1.7
BMI, kg/m2	33.4 ± 0.4	34.1 ± 0.4
Male/female, n	74/78	59/79
HbA1c, %	5.5 ± 0.3	5.5 ± 0.3
FPG, mg/dL	91.8 ± 0.7a	94.4 ± 0.7
2-h PG, mg/dL	134 ± 2.5a	149 ± 2.6
FPI, mU/L	10.1 ± 0.6	10.2 ± 0.5
Total Chol, mg/dL	170 ± 2	171 ± 7
LDL Chol, mg/dL	105 ± 2	106 ± 2
Triglyceride, mg/dL	121 ± 4	120 ± 2
HDL Chol, mg/dL	40.5 ± 7	40.9 ± 2
SBP, mm Hg	127 ± 1.1	127 ± 0.2
DBP, mm Hg	74 ± 0.6	73 ± 0.1

Abbreviations: BMI, body mass index; Chol, cholesterol; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FPI, fasting plasma insulin; LDL, low-density lipoprotein; PG, plasma glucose; SBP, systolic blood pressure.

^a P < .05, PIO vs PLAC.